Squamous Transition of Lung Adenocarcinoma and Drug Resistance

Area of Science:

• Oncology
• Cancer Biology
• Translational Research

Background:

• Lung adenocarcinoma (ADC) can transition to squamous cell carcinoma (SCC), a process termed AST.
• AST is implicated in the development of therapeutic resistance in lung cancer.
• Recent clinical findings suggest AST contributes to resistance in EGFR-mutant lung ADC patients undergoing TKI therapy and chemotherapy.

Purpose of the Study:

• To summarize the current understanding of the adenocarcinoma to squamous cell carcinoma transition (AST).
• To review the role of AST in the development of drug resistance in lung cancer.
• To discuss the clinical implications of AST in EGFR-mutant lung ADC patients.

Main Methods:

• Review of existing literature on AST and drug resistance.
• Analysis of preclinical mouse models.
• Examination of clinical observations in relapsed EGFR-mutant lung ADC patients.

Main Results:

• Mouse models demonstrate a critical role for AST in acquired drug resistance.
• Clinical data suggest AST is associated with resistance to TKI therapy and chemotherapy in relapsed EGFR-mutant lung ADC.
• Histological transition from ADC to SCC is a significant mechanism of treatment failure.

Conclusions:

• AST is a crucial mechanism underlying therapeutic resistance in lung cancer.
• Understanding AST is vital for developing strategies to overcome resistance in EGFR-mutant lung ADC.
• Targeting or preventing AST may improve treatment outcomes for lung cancer patients.